Yuanying Zeng

930 total citations
22 papers, 680 citations indexed

About

Yuanying Zeng is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Yuanying Zeng has authored 22 papers receiving a total of 680 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 9 papers in Hematology and 3 papers in Oncology. Recurrent topics in Yuanying Zeng's work include Ubiquitin and proteasome pathways (10 papers), Multiple Myeloma Research and Treatments (8 papers) and PI3K/AKT/mTOR signaling in cancer (7 papers). Yuanying Zeng is often cited by papers focused on Ubiquitin and proteasome pathways (10 papers), Multiple Myeloma Research and Treatments (8 papers) and PI3K/AKT/mTOR signaling in cancer (7 papers). Yuanying Zeng collaborates with scholars based in China, Canada and Singapore. Yuanying Zeng's co-authors include Xinliang Mao, Biyin Cao, Zubin Zhang, Yujia Xu, Shuoyi Jiang, Kunkun Han, Michael F. Moran, Jiefei Tong, Yuanming He and Siyu Wang and has published in prestigious journals such as Journal of Biological Chemistry, Blood and PLoS ONE.

In The Last Decade

Yuanying Zeng

22 papers receiving 672 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yuanying Zeng China 17 460 188 116 113 100 22 680
Abdurahman Alloghbi United States 7 317 0.7× 183 1.0× 73 0.6× 128 1.1× 91 0.9× 19 589
Mousheng Xu United States 11 300 0.7× 130 0.7× 97 0.8× 62 0.5× 53 0.5× 14 577
Antonio R. Lucena‐Araujo Brazil 16 404 0.9× 178 0.9× 223 1.9× 151 1.3× 153 1.5× 62 750
Vanessa S. Silveira Brazil 16 430 0.9× 117 0.6× 98 0.8× 32 0.3× 102 1.0× 32 648
Kathryn Date United Kingdom 6 237 0.5× 221 1.2× 47 0.4× 39 0.3× 133 1.3× 9 555
Erin E. Childs United States 10 243 0.5× 192 1.0× 84 0.7× 50 0.4× 108 1.1× 12 648
Nikolaos Soulitzis Greece 14 409 0.9× 265 1.4× 28 0.2× 216 1.9× 141 1.4× 28 768
Ayşe Özer Türkiye 14 225 0.5× 152 0.8× 47 0.4× 44 0.4× 115 1.1× 31 538
Daxun Piao China 16 482 1.0× 134 0.7× 36 0.3× 88 0.8× 229 2.3× 25 783
Haley E. Ramsey United States 17 464 1.0× 117 0.6× 335 2.9× 37 0.3× 96 1.0× 36 798

Countries citing papers authored by Yuanying Zeng

Since Specialization
Citations

This map shows the geographic impact of Yuanying Zeng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuanying Zeng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuanying Zeng more than expected).

Fields of papers citing papers by Yuanying Zeng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuanying Zeng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuanying Zeng. The network helps show where Yuanying Zeng may publish in the future.

Co-authorship network of co-authors of Yuanying Zeng

This figure shows the co-authorship network connecting the top 25 collaborators of Yuanying Zeng. A scholar is included among the top collaborators of Yuanying Zeng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuanying Zeng. Yuanying Zeng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Hongyue, Ziyang Liu, Ying Ren, et al.. (2025). Bardoxolone displays potent activity against triple negative breast cancer by inhibiting the TRIP13/STAT3 circuit. Acta Pharmacologica Sinica. 46(6). 1733–1741. 3 indexed citations
2.
He, Yuanming, Xiumin Zhou, Shuoyi Jiang, et al.. (2021). TRIM25 activates AKT/mTOR by inhibiting PTEN via K63-linked polyubiquitination in non-small cell lung cancer. Acta Pharmacologica Sinica. 43(3). 681–691. 41 indexed citations
3.
He, Yuanming, Shuoyi Jiang, Chenyu Mao, et al.. (2021). The deubiquitinase USP10 restores PTEN activity and inhibits non–small cell lung cancer cell proliferation. Journal of Biological Chemistry. 297(3). 101088–101088. 54 indexed citations
4.
Zhao, Zhi Gang, Fengyuan Li, Jialin Liu, et al.. (2020). The impact of individual lifestyle and status on the acquisition of COVID-19: A case—Control study. PLoS ONE. 15(11). e0241540–e0241540. 13 indexed citations
5.
Xu, Yujia, Tong Sun, Kun Zeng, et al.. (2020). Anti-bacterial and anti-viral nanchangmycin displays anti-myeloma activity by targeting Otub1 and c-Maf. Cell Death and Disease. 11(9). 818–818. 11 indexed citations
6.
Sun, Tong, Yujia Xu, Shuoyi Jiang, et al.. (2020). Suppression of the USP10/CCND1 axis induces glioblastoma cell apoptosis. Acta Pharmacologica Sinica. 42(8). 1338–1346. 50 indexed citations
7.
Zeng, Yuanying, Ping Xie, Xun Ye, et al.. (2020). COVID-19 with cystic features on computed tomography. Medicine. 99(18). e20175–e20175. 87 indexed citations
8.
Chen, Xuehan, Yujia Xu, Xiaoge Wang, et al.. (2019). Mebendazole elicits potent antimyeloma activity by inhibiting the USP5/c-Maf axis. Acta Pharmacologica Sinica. 40(12). 1568–1577. 33 indexed citations
9.
He, Yuanming, Siyu Wang, Jiefei Tong, et al.. (2019). The deubiquitinase USP7 stabilizes Maf proteins to promote myeloma cell survival. Journal of Biological Chemistry. 295(7). 2084–2096. 36 indexed citations
10.
Du, Yanyun, Yan Liu, Yujia Xu, et al.. (2018). The transmembrane protein TMEPAI induces myeloma cell apoptosis by promoting degradation of the c-Maf transcription factor. Journal of Biological Chemistry. 293(16). 5847–5859. 18 indexed citations
11.
Xu, Yujia, Zubin Zhang, Jie Li, et al.. (2017). The ubiquitin-conjugating enzyme UBE2O modulates c-Maf stability and induces myeloma cell apoptosis. Journal of Hematology & Oncology. 10(1). 132–132. 40 indexed citations
12.
Wang, Siyu, Zubin Zhang, Yanyun Du, et al.. (2017). Inhibition of the deubiquitinase USP5 leads to c-Maf protein degradation and myeloma cell apoptosis. Cell Death and Disease. 8(9). e3058–e3058. 69 indexed citations
13.
Wang, Siyu, Jie Li, Yanyun Du, et al.. (2017). The Class I PI3K inhibitor S14161 induces autophagy in malignant blood cells by modulating the Beclin 1/Vps34 complex. Journal of Pharmacological Sciences. 134(4). 197–202. 28 indexed citations
14.
Zeng, Yuanying, Xin Xu, Siyu Wang, et al.. (2017). Ring finger protein 6 promotes breast cancer cell proliferation by stabilizing estrogen receptor alpha. Oncotarget. 8(12). 20103–20112. 21 indexed citations
15.
Wang, Biao, et al.. (2016). Neutrophil gelatinase-associated lipocalin predicts myocardial dysfunction and mortality in severe sepsis and septic shock. International Journal of Cardiology. 227. 589–594. 22 indexed citations
16.
Xu, Xin, Kunkun Han, Xiaowen Tang, et al.. (2016). The Ring Finger Protein RNF6 Induces Leukemia Cell Proliferation as a Direct Target of Pre-B-cell Leukemia Homeobox 1. Journal of Biological Chemistry. 291(18). 9617–9628. 51 indexed citations
17.
Xu, Xin, Kunkun Han, Jingyu Zhu, et al.. (2016). An inhibitor of cholesterol absorption displays anti-myeloma activity by targeting the JAK2-STAT3 signaling pathway. Oncotarget. 7(46). 75539–75550. 17 indexed citations
18.
Han, Kunkun, Xin Xu, Guodong Chen, et al.. (2015). SC06, a novel small molecule compound, displays preclinical activity against multiple myeloma by disrupting the mTOR signaling pathway. Scientific Reports. 5(1). 12809–12809. 19 indexed citations
19.
Han, Kunkun, Xin Xu, Guodong Chen, et al.. (2014). Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization. Journal of Hematology & Oncology. 7(1). 9–9. 47 indexed citations
20.
Zhu, Jingyu, Man Wang, Yang Yu, et al.. (2014). A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma. Oncotarget. 6(1). 185–195. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Abdurahman Alloghbi Breakdown of academic impact, for papers by Mousheng Xu Breakdown of academic impact, for papers by Antonio R. Lucena‐Araujo Breakdown of academic impact, for papers by Vanessa S. Silveira Breakdown of academic impact, for papers by Kathryn Date Breakdown of academic impact, for papers by Erin E. Childs Breakdown of academic impact, for papers by Nikolaos Soulitzis Breakdown of academic impact, for papers by Ayşe Özer Breakdown of academic impact, for papers by Daxun Piao Breakdown of academic impact, for papers by Haley E. Ramsey
Rankless by CCL
2026